UNASSIGNED: 4646 Background: Hormone therapies for @entity263 block or lower the action of @entity251 , and @entity251 is related to @entity73 (Wolf _ Kirschbaum 2002). @entity251 supplementation can improve @entity2414 (Cherrier et al 2001). Cognitive functioning plays an important role in a @entity1 's quality of life but few studies have investigated the potential effects of anti- @entity342 therapy on cognition. METHODS: @entity1 (n=34) receiving temporary reversible medical castration with an LHRH agonist as neo-adjuvant hormone therapy prior to radical radiotherapy for @entity263 . Healthy controls (n=18) similar in age and intelligence to calculate a reliable change index. Each @entity1 was tested at baseline (T1) and followed up at three months (T2), and following the end of therapy at one year (T3). The same assessment of mood and cognition was made at every time-point. Serum @entity251 and @entity53 were measured alongside psychometric testing. The Cognitive test battery included tests of spatial ability, visual memory, working memory, verbal memory and processing speed. FACT P and General Health Questionnaire 12 were also administered. Reliable Change Index is a method of defining change in neuropsychological test scores that accounts for test reliability and practice effects, calculated from the control group's T1-T2 performance on each task. We looked at an individual @entity1 's change in scores to see whether scores fall outside the RC 90% CI Results: At T2 seven @entity1 remained above threshold on GHQ12. There were no overall group differences on the tasks. Biochemistry showed a significant drop in total _ free @entity251 and @entity53 levels (all p<0.0001). 16 @entity1 declined on the reliable change index as opposed to 3 controls. Of these 8/16 declined on one task, 6/16 declined on two tasks and 2/16 on three tasks. CONCLUSIONS: Changes are occurring for some @entity1 . Interview data with the T3 results (to be presented) will provide us with further information. No significant financial relationships to disclose.

A longitudinal pilot study to investigate whether hormonal therapy for XXXX affects cognition.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'participant', 'patient'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone', 'Testosterone'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localised prostate cancer', 'prostate cancer'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive ability'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['oestradiol'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity2414 :: ('MESH:D008569', 'Disease') :: ['spatial and verbal memory']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
